These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

579 related items for PubMed ID: 17256746

  • 21. Low risk of adefovir resistance in lamivudine-resistant chronic hepatitis B patients treated with adefovir plus lamivudine combination therapy: two-year follow-up.
    Yatsuji H, Suzuki F, Sezaki H, Akuta N, Suzuki Y, Kawamura Y, Hosaka T, Kobayashi M, Saitoh S, Arase Y, Ikeda K, Watahiki S, Iwasaki S, Kobayashi M, Kumada H.
    J Hepatol; 2008 Jun; 48(6):923-31. PubMed ID: 18433925
    [Abstract] [Full Text] [Related]

  • 22. Safety and efficacy of adefovir therapy for lamivudine-resistant hepatitis B virus infection in renal transplant recipients.
    Lai HW, Chang CC, Chen TH, Tsai MC, Chen TY, Lin CC.
    J Formos Med Assoc; 2012 Aug; 111(8):439-44. PubMed ID: 22939662
    [Abstract] [Full Text] [Related]

  • 23. Adefovir rapidly suppresses hepatitis B in HBeAg-negative patients developing genotypic resistance to lamivudine.
    Lampertico P, Viganò M, Manenti E, Iavarone M, Lunghi G, Colombo M.
    Hepatology; 2005 Dec; 42(6):1414-9. PubMed ID: 16317671
    [Abstract] [Full Text] [Related]

  • 24. Evolution of full-length HBV sequences in chronic hepatitis B patients with sequential lamivudine and adefovir dipivoxil resistance.
    Chen CH, Lee CM, Tung WC, Wang JH, Hung CH, Hu TH, Wang JC, Lu SN, Changchien CS.
    J Hepatol; 2010 Apr; 52(4):478-85. PubMed ID: 20185198
    [Abstract] [Full Text] [Related]

  • 25. Clinical course and predictive factors of virological response in long-term lamivudine plus adefovir dipivoxil combination therapy for lamivudine-resistant chronic hepatitis B patients.
    Aizawa M, Tsubota A, Fujise K, Tatsuzawa K, Kono M, Hoshina S, Tajiri H.
    J Med Virol; 2011 Jun; 83(6):953-61. PubMed ID: 21503906
    [Abstract] [Full Text] [Related]

  • 26. Antiviral efficacy of combination therapy with entecavir and adefovir for entecavir/lamivudine-resistant hepatitis B virus with or without adefovir resistance.
    Yang HJ, Lee JH, Kim YJ, Yoon JH, Lee HS.
    J Med Virol; 2012 Mar; 84(3):424-30. PubMed ID: 22246827
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. Comparison of the 48-week efficacy of Lamivudine plus Adefovir or Entecavir monotherapy in patients with HBeAg negative hepatitis following Lamivudine treatment failure.
    Zhang Q, Zhang L, Xing Y, Qin Y, Liu G.
    Acta Gastroenterol Belg; 2019 Mar; 82(1):31-34. PubMed ID: 30888751
    [Abstract] [Full Text] [Related]

  • 29. Efficacy of switching to telbivudine plus adefovir in suboptimal responders to lamivudine plus adefovir.
    Park H, Park JY, Kim SU, Kim DY, Han KH, Chon CY, Ahn SH.
    World J Gastroenterol; 2013 Mar; 19(43):7671-9. PubMed ID: 24431895
    [Abstract] [Full Text] [Related]

  • 30. Initial virological response and viral mutation with adefovir dipivoxil added to ongoing Lamivudine therapy in Lamivudine-resistant chronic hepatitis B.
    Wu S, Fukai K, Imazeki F, Arai M, Kanda T, Yonemitsu Y, Yokosuka O.
    Dig Dis Sci; 2011 Apr; 56(4):1207-14. PubMed ID: 20927588
    [Abstract] [Full Text] [Related]

  • 31. Long-term efficacy and safety of adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B.
    Marcellin P, Chang TT, Lim SG, Sievert W, Tong M, Arterburn S, Borroto-Esoda K, Frederick D, Rousseau F.
    Hepatology; 2008 Sep; 48(3):750-8. PubMed ID: 18752330
    [Abstract] [Full Text] [Related]

  • 32. Evaluation of initial virological response to adefovir and development of adefovir-resistant mutations in patients with chronic hepatitis B.
    Gallego A, Sheldon J, García-Samaniego J, Margall N, Romero M, Hornillos P, Soriano V, Enrĺquez J.
    J Viral Hepat; 2008 May; 15(5):392-8. PubMed ID: 18221300
    [Abstract] [Full Text] [Related]

  • 33. Efficacy and safety of telbivudine plus adefovir dipivoxil combination therapy and entecavir monotherapy for HBeAg-positive chronic hepatitis B patients with resistance to adefovir dipivoxil.
    Lu JJ, Liu K, Ma YJ, Wang J, Chen EQ, Tang H.
    J Viral Hepat; 2013 Apr; 20 Suppl 1():40-5. PubMed ID: 23458523
    [Abstract] [Full Text] [Related]

  • 34. Virologic responses to add-on adefovir dipivoxil treatment versus entecavir monotherapy in children with lamivudine-resistant chronic hepatitis B.
    Chu M, Cho SM, Choe BH, Cho MH, Kwon S, Lee WK.
    J Pediatr Gastroenterol Nutr; 2012 Dec; 55(6):648-52. PubMed ID: 22688509
    [Abstract] [Full Text] [Related]

  • 35. Tenofovir vs lamivudine plus adefovir in chronic hepatitis B: TENOSIMP-B study.
    Rodríguez M, Pascasio JM, Fraga E, Fuentes J, Prieto M, Sánchez-Antolín G, Calleja JL, Molina E, García-Buey ML, Blanco MÁ, Salmerón J, Bonet ML, Pons JA, González JM, Casado MÁ, Jorquera F, TENOSIMP-B Research Group.
    World J Gastroenterol; 2017 Nov 07; 23(41):7459-7469. PubMed ID: 29151700
    [Abstract] [Full Text] [Related]

  • 36. [Factors associated with response to lamivudine: retrospective study of 233 patients with chronic hepatitis B].
    Zhou HJ, Li SG, Wen FY, Yang XY, Wu JL, Tan B, Fu J.
    Zhonghua Gan Zang Bing Za Zhi; 2009 Aug 07; 17(8):564-8. PubMed ID: 19719911
    [Abstract] [Full Text] [Related]

  • 37. Comparison of lamivudine plus adefovir therapy versus entecavir with or without adefovir therapy for adefovir-resistant chronic hepatitis B.
    Kang SH, Yim HJ, Kim HR, Kang K, Suh SJ, Lee HJ, Yoon EL, Kim JH, Seo YS, Yeon JE, Byun KS.
    J Clin Gastroenterol; 2014 Aug 07; 48(10):889-95. PubMed ID: 24440937
    [Abstract] [Full Text] [Related]

  • 38. [A clinical study of adefovir dipivoxil, made in China, for treatment of hepatitis B e antigen-positive patients with chronic hepatitis B].
    Lin XH, Si CW, Yu YY, Li J, Chen XY, Ren XM, Liu P, Zhang SL, Kang XP.
    Zhonghua Gan Zang Bing Za Zhi; 2006 Dec 07; 14(12):898-901. PubMed ID: 17196132
    [Abstract] [Full Text] [Related]

  • 39. Comparison of entecavir monotherapy and de novo lamivudine and adefovir combination therapy in HBeAg-positive chronic hepatitis B with high viral load: 48-week result.
    Cai S, Yu T, Jiang Y, Zhang Y, Lv F, Peng J.
    Clin Exp Med; 2016 Aug 07; 16(3):429-36. PubMed ID: 26164128
    [Abstract] [Full Text] [Related]

  • 40. [Three year adefovir dipivoxil treatment for hepatitis B e antigen-positive chronic hepatitis B patients].
    Ling N, Zhou Z, Zhang DZ, Ren H.
    Zhonghua Gan Zang Bing Za Zhi; 2007 May 07; 15(5):346-9. PubMed ID: 17524266
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 29.